Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1.
Burzynski SR, Kubove E, Burzynski B. Burzynski SR, et al. Among authors: kubove e. Drugs Exp Clin Res. 1990;16(7):361-9. Drugs Exp Clin Res. 1990. PMID: 2152694 Clinical Trial.
Toxicology studies on antineoplaston A10 injections in cancer patients.
Burzynski SR, Kubove E. Burzynski SR, et al. Among authors: kubove e. Drugs Exp Clin Res. 1986;12 Suppl 1:47-55. Drugs Exp Clin Res. 1986. PMID: 3743380
Phase I clinical studies of antineoplaston A5 injections.
Burzynski SR, Kubove E, Burzynski B. Burzynski SR, et al. Among authors: kubove e. Drugs Exp Clin Res. 1987;13 Suppl 1:37-43. Drugs Exp Clin Res. 1987. PMID: 3569014
Phase I clinical studies of antineoplaston A3 injections.
Burzynski SR, Kubove E. Burzynski SR, et al. Among authors: kubove e. Drugs Exp Clin Res. 1987;13 Suppl 1:17-29. Drugs Exp Clin Res. 1987. PMID: 3569012
Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up.
Burzynski SR, Kubove E. Burzynski SR, et al. Among authors: kubove e. Drugs Exp Clin Res. 1987;13 Suppl 1:1-11. Drugs Exp Clin Res. 1987. PMID: 3569010
Feedback